Waters Corporation launches Cyclic IMS P20
Analysis based on 9 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026
The launch of the Waters Cyclic IMS P20 Mass Spectrometer by Oracle Corporation is expected to positively impact the company's stock price due to enhanced product offerings and potential market share gains. This technological advancement could also drive innovation and competition within the biotechnology and pharmaceutical industries, benefiting companies involved in drug discovery and disease detection.
Oracle Corporation announced the launch of its new Waters Cyclic IMS P20 Mass Spectrometer at the 74th ASMS Conference on Mass Spectrometry and Allied Topics. This high-resolution structural and spatial omics platform offers a more than 10-fold increase in MS/MS sensitivity and an extended upper mass range, enabling earlier detection of disease signals and advancing biotherapeutic development. The system integrates MALDI XS and DESI XS imaging with high-resolution ion mobility for direct visualization of molecules in tissue. James Hallam of Oracle Corporation and Kostas Thalassinos of University College London highlighted the instrument's capabilities in accelerating analyses and understanding disease mechanisms. The product is expected to be globally available starting September 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard